On Wednesday, Intra-Cellular Therapies Inc (NASDAQ:ITCI)’s shares inclined 86.86% to $48.79.
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, recently declared positive results from the first Phase 3 clinical trial of ITI-007 for the treatment of patients with schizophrenia. In this trial, once-daily ITI-007 60 mg met the primary endpoint and demonstrated antipsychotic efficacy with statistically noteworthysuperiority over placebo at Week 4 (study endpoint) as measured by the change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score (p=0.022). Moreover, ITI-007 60 mg showed noteworthyantipsychotic efficacy as early as week 1, which was maintained at every time point throughout the entire study. ITI-007 60 mg also met the key secondary endpoint of statistically noteworthyimprovement on the Clinical Global Impression Scale for Severity of Illness (CGI-S; p=0.003). These findings confirm the positive results demonstrated by ITI-007 60 mg in the Company’s Phase 2 study. Compriseent with previous studies, ITI-007 had a favorable safety and tolerability profile as evidenced by motoric, metabolic, and cardiovascular characteristics similar to placebo, and no clinically noteworthychanges in akathisia, extrapyramidal symptoms, prolactin, body weight, glucose, insulin, or lipids.
The Company also declared top-line data from a separate clinical study using positron emission tomography (PET) in patients with schizophrenia. In this trial, ITI-007 60 mg was associated with a mean of about 40% striatal dopamine D2 receptor occupancy. As predicted by preclinical and earlier clinical data, ITI-007 demonstrated antipsychotic effect at relatively low striatal D2 receptor occupancy, lower than the occupancy range required by most other antipsychotic drugs. Unlike any existing schizophrenia treatment, this dopamine receptor phosphoprotein modulator, or DPPM, acts as a pre-synaptic partial agonist and post-synaptic antagonist at D2 receptors. This mechanism likely contributes to the favorable safety profile of ITI-007, with reduced risk for hyperprolactinemia, akathisia, extrapyramidal symptoms, and other motoric side effects. The data from both clinical trials will be presented at forthcoming scientific meetings.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system (CNS). Its lead drug candidate is ITI-007, which is in phase III clinical development for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder, depression, and other neuropsychiatric and neurological disorders.
Atmel Corporation (NASDAQ:ATML)’s shares dropped -0.24% to $8.18.
Atmel® Corporation (ATML), a leader in microcontroller (MCU) and touch technology solutions, declared the company has expanded its robust portfolio of automotive-qualified maXTouch® touchscreen controllers with the mXT641T family. The new family is optimized for capacitive touchpads and touchscreens from 5 to 10 inches. These mXT641T devices are the industry’s first auto-qualified self- and mutual-capacitance controllers meeting the AEC-Q100 standards for high reliability in harsh environments.
The automotive-qualified maXTouch mXT641T family incorporates Atmel’s Adaptive Sensing technology to enable dynamic touch classification, a feature that automatically and intelligently switches between self- and mutual-capacitance sensing to provide users a seamless transition between a finger touch, hover, or glove touch. It eliminates the need for users to manually enable ‘glove mode’ in the operating system to differentiate between hover and glove modes. Adaptive Sensing is also resistant to water and moisture and ensures superior touch performance even in these harsh conditions.
The new devices support stringent automotive requirements counting hover and glove support in moist and cold environments, thick lens for better impact resistance, and single-layer shieldless sensor designs in automotive center consoles, navigation systems, radio interfaces and rear-seat entertainment systems. The single-layer shieldless sensor design eliminates additional screen layers, delivering better light transparency resulting in lower power consumption together with an overall lower system cost for the manufacturer.
Atmel Corporation designs, develops, manufactures, and sells semiconductor integrated circuit products primarily in the United States, Asia, Europe, South Africa, and Central and South America. It operates in four segments: Microcontroller, Nonvolatile Memory, Automotive, and Multi-Market and Other.
At the end of Wednesday’s trade, Las Vegas Sands Corp. (NYSE:LVS)‘s shares surged 2.61% to $48.72.
Sands China Ltd. (HK), a majority owned partner of global resort developer Las Vegas Sands (LVS) recently declared the appointment of Wilfred Wong, GBS, JP, as the company’s new president and chief operating officer. Mr. Wong’s appointment is effective November 1, 2015 and he will replace Rob Goldstein (current president and COO of LVS), who has been serving as Sands China’s interim president since earlier this year.
Mr. Wong is joining Sands China after having served in a variety of senior business roles, counting most recently as chairman and chief executive officer of the Hong Kong listed Hsin Chong Construction Group Ltd. Mr. Wong also held top administration positions in a number of other Hong Kong listed companies in the property development and construction business sectors, counting K. Wah International Holdings Limited, Henderson China Holdings Limited and the Shui On Group.
Las Vegas Sands Corp. develops, owns, and operates integrated resorts in Asia and the United States. The company owns and operates The Venetian Macao Resort Hotel, Sands Cotai Central, the Four Seasons Hotel Macao, the Plaza Casino, and the Sands Macao in Macau, the Peoples Republic of China.
Texas Instruments Incorporated (NASDAQ:TXN), ended its Wednesday’s trading session with 0.83% gain, and closed at $48.70.
Texas Instruments Incorporated (TI) (TXN) Vice President Dave Pahl will speak at the 2015 Deutsche Bank Technology Conference in Las Vegas on Thursday, September 17, at 2:40 p.m. Pacific time. Pahl will field questions from analysts and investors, in addition to talk about TI’s business outlook and its strategy to address key markets for its analog and embedded processing technologies and how these capabilities position the company for growth.
Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers worldwide. It operates through two segments, Analog and Embedded Processing.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
